After a funky music introduction, Richard Lazar of DeltaPoint jumped on stage an presented which appears to be an important company in the fight against cancer.

http://deltapointinc.com/index.php

DelaPoint’s software non-invasive diagnoses cancer by analyzing contrast enhanced MRI imaging studies.

Problem/Solution:  500,000 women per year referred for post-imaging breast biopsies don’t have cancer (“false positives”).  Up to 50,000 breast biopsies per year don’t find cancers that are present.

DeltaPoint software is tackling:

o   Find more breask cancers earlier in their development

o   Aid in biopsy planning through the use of 3-D visualization techniques

o   Significantly decrease the number and risk of “false negative” biopsies

o   Meaningfully reduce the number and cost of unnecessary “false positive” biopsies

o   Help objectively quantify BI-RADS (Breast Imaging-Reporting and Data System) assessments

Reasons to invest.

o   Big potential initial market with large follow on opportunities

o   Novel, protected science behind the technology

o   Experienced, previously successful team, especially Richard Lazar

o   Exclusive license with OHSU is done

o   Solid FDA and SBIR prospects, but still have risks/concerns

o   Reasonable exit strategy—active high multiple M&A activity in this arena

Concerns (with Richard's responses sumarized in CAPS):

FDA risk – 501k plan is reasonable, but still has reisks is terms of time & money

                WE WILL GET THROUGH FDA. HIRE QUALITY ATTORNEY. FDA APPROVAL IS PROGRESSING.

Funding risks—company will need another $4-6 m, but good shot at NIH SBIR grants and VC funding

                WE HAVE RELATIVELY LOW FUNDING RISK IN COMPARISON TO OTHERS IN THIS SPACE.  BRANDING SUPPORT. OBAMA-CARE—WE WIN IN AN INTERGRATE HEALTHCARE APPROACH.

Questions.

o   7 years is a long time (investment/sustainability).  Things will change, but this cancer epidemic is here to stay.

o   Legal/liability.